On January 12, 2026, Mirador Therapeutics, Inc., a clinical-stage precision medicine company developing next-generation therapies for immune-mediated inflammatory and fibrotic diseases, announced it has closed a $250 million Series B financing, bringing total capital raised to more than $650 million since the company launched in March 2024. The proceeds enable Mirador to deliver proof-of-concept across all current programs and support the development of additional pipeline candidates. Wilson Sonsini Goodrich & Rosati has advised Mirador on patent matters since the company’s inception, and counseled Mirador on patent matters related to this latest transaction.

The Wilson Sonsini team that advised Mirador on patent matters included Matt Bresnahan, Alicia Umpierre, and Ryan Lin.

For more information, please see Mirador's press release.